|Bid||24.13 x 800|
|Ask||24.14 x 800|
|Day's Range||23.33 - 24.31|
|52 Week Range||18.08 - 27.80|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||68.97|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.36|
Over the long run, value stocks have outperformed growth stocks on an annualized basis. Historically low lending rates and a highly accommodative Federal Reserve have rolled out the red carpet for fast-growing companies looking to borrow at extremely cheap rates. As we move headlong into the second quarter, the following three growth stocks stand out for having all the tools needed to make investors a lot richer.
The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors. As a next-generation tissue factor-targeting antibody-drug conjugate (ADC), XB002 has the potential for an improved therapeutic index and may provide a favorable safety profile compared with earlier-generation tissue factor-targeting ADCs.